Pharmaceutical Executive-05-01-2011

Sizing Up For Success

Rising income per capita and a budding consumer health consciousness are fueling a CAGR of 9.5%, giving investors plenty of room to expand market penetration

According to Eli Lilly, managing alliances requires more than good people skills

The UK coalition government's consultation on the intro of value-based pricing has invited caution and resistance

To what extent are generics companies obligated by law to request labeling changes with FDA?

Online sentiment analysis monitoring can help biopharma resource managers make crucial decisions

The sleek, portable iPad, coupled with customized apps, gives sales reps a leg up

Considering Big Pharma's trade objectives, the success of regional regulatory harmonization is not insignificant

Stiff price tags draw scrutiny from Congress and consumers, and raise questions about FDA policies

The EU is largely powerless when it comes to policies over pricing and reimbursement

A factory tour to examine Merck's automated robots-and the human minds that inspire them

What do the Pharm Exec 50 numbers tell us? The dominant theme seems to be one of gradual restructuring toward a post-patent-cliff era.

The pharmaceutical industry needs to use new and better data to accurately measure how much it is willing to invest in avoiding plan control